Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2012 Oct 01;1673:654-65. doi: 10.1111/j.1476-5381.2012.02030.x.
Show Gene links
Show Anatomy links
Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol.
Broberg Ml
,
Holm R
,
Tønsberg H
,
Frølund S
,
Ewon KB
,
Nielsen Al
,
Brodin B
,
Jensen A
,
Kall MA
,
Christensen KV
,
Nielsen CU
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Intestinal absorption via membrane transporters may determine the pharmacokinetics of drug compounds. The hypothesis is that oral absorption of gaboxadol (4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-ol) in rats occurs via the proton-coupled amino acid transporter, rPAT1 (encoded by the gene rSlc36a1). Consequently, we aimed to elucidate the in vivo role of rPAT1 in the absorption of gaboxadol from various intestinal segments obtained from Sprague-Dawley rats.
EXPERIMENTAL APPROACH: The absorption of gaboxadol was investigated following its administration into four different intestinal segments. The intestinal expression of rSlc36a1 mRNA was measured by quantitative real-time PCR. Furthermore, the hPAT1-/rPAT1-mediated transport of gaboxadol or L-proline was studied in hPAT1-expressing Xenopus laevis oocytes, Caco-2 cell monolayers and excised segments of the rat intestine.
KEY RESULTS: The absorption fraction of gaboxadol was high (81.3-91.3%) following its administration into the stomach, duodenum and jejunum, but low (4.2%) after administration into the colon. The pharmacokinetics of gaboxadol were modified by the co-administration of L-tryptophan (an hPAT1 inhibitor) and L-proline (an hPAT1 substrate). The in vitro carrier-mediated uptake rate of L-proline in the excised intestinal segments was highest in the mid jejunum and lowest in the colon. The in vitro uptake and the in vivo absorption correlated with the expression of rSlc36a1 mRNA along the rat intestine.
CONCLUSIONS AND IMPLICATIONS: These results suggest that PAT1 mediates the intestinal absorption of gaboxadol and therefore determines its oral bioavailability. This has implications for the in vivo role of PAT1 and may have an influence on the design of pharmaceutical formulations of PAT1 substrates.
Abbot,
Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1.
2006, Pubmed,
Xenbase
Abbot,
Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1.
2006,
Pubmed
,
Xenbase
Alexander,
New updated GRAC Fifth Edition with searchable online version Launch of new portal Guide to Pharmacology in association with NC-IUPHAR Transporter-Themed Issue.
2011,
Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011,
Pubmed
Anderson,
H+/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat.
2004,
Pubmed
,
Xenbase
Anderson,
Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+- and Cl(-)-dependent TauT (SLC6A6).
2009,
Pubmed
,
Xenbase
Boll,
Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransporters.
2002,
Pubmed
,
Xenbase
Chen,
Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2.
2003,
Pubmed
Chen,
A novel simultaneous measurement method to assess the influence of intracerebroventricular obestatin on colonic motility and secretion in conscious rats.
2010,
Pubmed
Choudhuri,
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.
2006,
Pubmed
Christensen,
Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.
2010,
Pubmed
Dobson,
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
2008,
Pubmed
Englund,
Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells.
2006,
Pubmed
Foltz,
Kinetics of bidirectional H+ and substrate transport by the proton-dependent amino acid symporter PAT1.
2005,
Pubmed
,
Xenbase
Frølund,
Gaboxadol has affinity for the proton-coupled amino acid transporter 1, SLC36A1 (hPAT1)--A modelling approach to determine IC(50) values of the three ionic species of gaboxadol.
2011,
Pubmed
Frølund,
Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1).
2010,
Pubmed
Frølund,
The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics.
2010,
Pubmed
,
Xenbase
Giacomini,
Membrane transporters in drug development.
2010,
Pubmed
Herrera-Ruiz,
Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues.
2001,
Pubmed
Holm,
Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats.
2012,
Pubmed
,
Xenbase
Howard,
Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by TPN is reversed by GLP-2.
2004,
Pubmed
Kall,
Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection.
2007,
Pubmed
Kilkenny,
Animal research: reporting in vivo experiments: the ARRIVE guidelines.
2010,
Pubmed
Larsen,
5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination.
2010,
Pubmed
,
Xenbase
Larsen,
Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan.
2009,
Pubmed
Larsen,
Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells.
2008,
Pubmed
Livak,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
2001,
Pubmed
McGrath,
Guidelines for reporting experiments involving animals: the ARRIVE guidelines.
2010,
Pubmed
Metzner,
Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.
2005,
Pubmed
,
Xenbase
Naruhashi,
PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine.
2002,
Pubmed
Sai,
Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition.
2005,
Pubmed
Schmittgen,
Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods.
2000,
Pubmed
Sugano,
Coexistence of passive and carrier-mediated processes in drug transport.
2010,
Pubmed
Tannergren,
Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
2009,
Pubmed
Thwaites,
The role of the proton electrochemical gradient in the transepithelial absorption of amino acids by human intestinal Caco-2 cell monolayers.
1995,
Pubmed
Thwaites,
H(+)-coupled (Na(+)-independent) proline transport in human intestinal (Caco-2) epithelial cell monolayers.
1993,
Pubmed
Thwaites,
Gamma-Aminobutyric acid (GABA) transport across human intestinal epithelial (Caco-2) cell monolayers.
2000,
Pubmed
Ziegler,
Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome.
2002,
Pubmed
